ABSTRACT. The effects of the leukotriene antagonist FPL 57231 on the circulation were studied in spontaneously breathing normoxic and hypoxic newborn lambs in order to evaluate the role of leukotrienes in the perinatal control of hypoxic pulmonary vasoconstriction. Hypoxia produced a 58% increase in pulmonary arterial pressure The exact mechanisms by which hypoxia produces pulmonary vasoconstriction remain unknown. The production and release of the noncyclooxygenase products of arachidonic acid from the lung may play an important role. Leukotrienes, the 5'-lipoxygenase metabolites of arachidonic acid, are produced by mast cells (1, 2), alveolar macrophages (3), and pulmonary vascular tissue (4-6). Leukotrienes induce smooth muscle contraction in a variety of tissues (7-10). Leukotriene D4 infused into the pulmonary artery of young lambs produces pulmonary arterial hypertension (1 1). Leukotriene inhibition with FPL 57231 (Fisons, plc, Loughborough, UK), a leukotriene receptor antagonist (12), significantly increases pulmonary blood flow and decreases pulmonary vascular resistance in fetal lambs (1 3). Leukotrienes have been isolated from the lung lavage fluid of newborn infants with persistent pulmonary hypertension syndrome but not from newborn infants with other lung diseases (14). These findings suggest that leukotrienes may play a role in maintaining the elevated pulmonary vascular tone in the normal fetus in utero and also in the mediation of hypoxic pulmonary vasoconstriction after birth. The effects of the leukotriene antagonist FPL 5723 1 on the circulation were therefore studied in normoxic and hypoxic spontaneously breathing newborn lambs.
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METHODS
Surgical procedure and drug preparation. Six mixed-breed newborn lambs from 3-7 days old were operated on under local anesthesia with 1 % lidocaine hydrochloride. Polyvinyl catheters were placed in both hind limb arteries and veins and advanced to the descending aorta and inferior vena cava, respectively. A no. 5 French flow-directed thermodilution catheter, with the proximal injection port 15 cm from the tip, was introduced into the jugular vein and advanced into the pulmonary artery for measuring pulmonary arterial and pulmonary arterial wedge pressures. Right atrial pressure was measured through the proximal port. Cardiac output was determined by the thermodilution technique and calculated by computer (Electro-Catheter model 5000, Electro-Catheter Corp., Rahway, NJ). Three milliliters of iced-saline was injected into the proximal port for each measurement. Each cardiac output value was taken as the average of three determinations. Following surgery, the lambs were placed in a sling under a radiant warmer to maintain body temperature. An intravenous infusion of dextrose in water was started. Two horns were allowed for recovery.
FPL 5723 1 was prepared immediately before each experiment as a 1 % solution in sterile water.
Experimental Protocol. FPL 57231 infusion prior to the onset of hypoxia. Following the recovery period, baseline vascular pressures, cardiac output, and arterial blood gas measurements were made in room air (NORMOXIA). Normocarbic hypoxia was then induced by placing a loosely fitting bag over the lamb's head and adding nitrogen with 5% C02 to the gas mixture. The F102 was varied to produce a Pao2 of 30-40 mm Hg in each animal. Measurements were made after 10 rnin of hypoxia and stable pulmonary hypertension (HYPOXIA). The lamb was returned to room air.
After the lambs resumed baseline values (NORMOXIA), an intravenous infusion of FPL 5723 1 (1 mg. kg-'. min-I) for 20 rnin was started. Measurements were made after 10 rnin of the infusion (NORMOXIA + FPL 57231). Hypoxia was then induced as the drug infusion continued, and measurements were made after another 10 rnin (HYPOXIA + FPL 57231). The infusion was stopped as hypoxia continued, and measurements were made after 15 min. The lambs were returned to room air. Measurements were also made with an equivalent infusion of sterile water vehicle during normoxia and hypoxia.
FPL 57231 infusion started during hypoxia. Six to 24 hr were allowed for recovery from the above experiment. In five lambs baseline measurements were made in room air (NORMOXIA). Normocarbic hypoxia was again induced producing hypoxemia (Pao* 30-40 mm Hg) and stable pulmonary hypertension. After 10 min, measurements were repeated (HYPOXIA). Hypoxia was continued and an infusion of FPL 5723 1 (2 m g kg-'. min-') was started. Measurements were made after 10 min (HYPOXIA + FPL 5723 1). The drug infusion was then stopped, and the lambs were returned to room air.
Measurements and calculations.
Pulmonary and systemic arterial and right atrial pressures were measured with Statham P23 Db pressure transducers and recorded continuously on a Beckman multichannel direct-writing recorder. Mean pressures were obtained by electrical integration. Heart rate was measured with a cardiotachometer triggered from the systemic arterial pressure. Cardiac output, pulmonary arterial wedge pressure, and systemic arterial blood gases were measured during all normoxia and hypoxia periods after a steady-state had been reached. The absence of intracardiac shunting was determined by indicator dilution technique. The validity of the thermodilution method has been reported previously ( 15, 16) . Pulmonary vascular resistance was calculated as the mean pulmonary arterial pressure minus mean pulmonary arterial wedge pressure divided by cardiac output per kilogram. Systemic vascular resistance was calculated as the mean systemic arterial pressure minus mean right atrial pressure divided by cardiac output per kilogram.
The mean f SD was computed for the vascular pressures, resistances, cardiac output, heart rate, and arterial blood gases during all normoxic and hypoxic conditions. The differences in these variables were compared by two-way analysis of variance and the Newman-Keuls test for multiple comparisons (I 7). A p c 0.05 was considered statistically significant. (Table l) , pH, and PCOZ (Table 2) did not change throughout the study. Pao2 and arterial saturation were unchanged during normoxic as well as during hypoxic conditions (Table 2 ). Infusion of vehicle did not affect the hemodynamic variables or arterial blood gases during either normoxia or hypoxia.
RESULTS

FPL
FPL 5 7231 infusion started during hypoxia ( Table 3 , Fig. 2) . The hemodynamic variables, arterial blood gases, and the response to hypoxia were similar to the above experiment. During hypoxia-induced pulmonary arterial hypertension, infusing FPL 5723 1 (HYPOXIA + FPL 5723 1) decreased pulmonary arterial pressure by 35% ( p < 0.05) and pulmonary vascular resistance by 37% ( p < 0.05) from HYPOXIA. There were small, but not statistically significant, decreases in systemic arterial pressure and systemic vascular resistance from HYPOXIA. The 13% increase in cardiac output induced by hypoxia was not lowered by the infusion of FPL 57231. Right atrial and pulmonary arterial wedge pressures, pH, and Pcoz were unchanged. P a q and arterial saturation were similar during both hypoxic conditions. Whether the infusion of FPL 5723 1 was started prior to or during hypoxia, pulmonary arterial pressure and pulmonary vascular resistance were similarly affected.
DISCUSSION
The results of this study indicate that an infusion of FPL 57231, a competitive leukotriene receptor antagonist (12), prevents pulmonary vasoconstriction with hypoxia and reverses hypoxia-induced pulmonary hypertension in the newborn lamb. There is no attenuation of the hypoxia-induced increase in cardiac output. Systemic arterial pressure decreased slightly. Whether these effects are caused by leukotriene antagonism or inhibition or activation of other substances, or are direct vascular of anaphylaxis, and/or via the cyclooxygenase pathway to prostaglandins (2-6, 19, 20) . PG12, PGD2, and PGE2 are pulmonary vasodilators in fetal and newborn animals (2 1,22). Interestingly, PGD2 is a pulmonary vasoconstrictor in older animals (22) . PGF2 is a pulmonary vasoconstrictor in fetal and newborn animals (2 1). The effects of thromboxanes, potent smooth muscle constrictors, on the perinatal pulmonary circulation are not known. Thromboxane levels are elevated, however, during pulmonary hypertension associated with endotoxin infusion in newborn lambs (23) . LTC4 and LTD4 are not only potent pulmonary vasoconstrictors but also stimulate the synthesis of thromboxane and other prostaglandins (24) (25) (26) (27) . This leukotriene-induced synthesis of thromboxane and other prostaglandins can be blocked by both indomethacin, a cyclooxygenase inhibitor (26, 27) , and FPL 557 12 (25, 28) , indicating an interrelationship between the leukotriene and prostaglandin synthetic pathways. FPL 55712, the parent compound of FPL 57231, is one of a series of chromone-2-carboxylic acids ( 12) . FPL 557 12 has been shown to inhibit leukotriene constrictor activity in many tissues including pulmonary vascular, lung parenchymal, and tracheal strips in guinea pig and man (8) (9) (10) 12) . FPL 557 12 has other in vitro effects. In concentrations greater than 1.0 x M, FPL 55712 inhibits thromboxane production from human platelet microsomes (28) . It also prevents anaphylaxis-induced thromboxane, PG12, and PGE2 production and release from guinea pig lung (19, 25, 26) . PGD2 production, however, is not inhibited (19) . Whether these effects occur in vivo is not known.
In the intact animal, FPL 55712 inhibits the coronary artery vasoconstriction and improves the myocardial contractility impairment produced by the intracoronary injection of LTD4 into sheep (29) . FPL 557 12 also increases pulmonary blood flow and decreases pulmonary vascular resistance in late gestation fetal lambs (30) .
FPL 57231, the compound used in this study, is a proprionic acid analog of FPL 557 12. FPL 5723 1 produces a similar degree of leukotriene antagonism with less antiallergic effects (12) . Both compounds are rapidly cleared from the plasma, with a serum half-life of < 10 min, and have a similar duration of action (1 2).
In adult sheep, FPL 5723 1 attenuates hypoxic pulmonary vasoconstriction (7). In near term fetal lambs, intrapulmonary infusions of FPL 57231 markedly increase pulmonary blood flow and decrease pulmonary vascular resistance (1 3). In preliminary studies in four newborn lambs, FPL 57231 (1 mg/kg/min) completely blocked the hemodynamic effects of intravenously injected LTD4.
Leukotriene receptor stimulation may produce direct cardiovascular changes and induce thromboxane and PG synthesis (24) (25) (26) (27) 31) . These formed substances may add to the overall hemodynamic effects. FPL 55712 blocks both the direct leukotriene effects and the effects produced by PG and thromboxane synthesis (7-9, 26, 28). FPL 5723 1 also blocks the direct effects of leukotriene (12) but its effect on PG production is not known.
In newborn lambs, the intrapulmonary injection of 1 pg. kg-' of LTD4 increases pulmonary vascular resistance by more than 300%. There is also a biphasic effect on the systemic circulation with an initial fall in systemic vascular resistance followed by a 200% increase. Pretreatment with indomethacin partially blunts the increase in pulmonary vascular resistance and abolishes the initial decrease in systemic vascular resistance (1 1). In adult sheep, FPL 5723 1 but not indomethacin blocks hypoxia-induced pulmonary hypertension, while both alter the pulmonary vascular response to infused LTD4 (7, 32) . This interaction between leukotrienes and PG may be important in controlling the pulmonary circulation.
Leukotriene antagonism through both receptor blockade with FPL 55712 and synthesis inhibition with diethylcarbamazine citrate attenuates hypoxic pulmonary vasoconstriction in isolated perfused rat lungs (33) . The results of this and the above studies (7,33) indicate a role for leukotrienes in the mediation of hypoxic pulmonary vasoconstriction. Similarly, FPL 557 12 blocks exogenous LTC4-induced pulmonary vasoconstriction, with no effect on angiotension 11-induced vasoconstriction (33) . These results suggest a specific capacity for leukotriene antagonists to block leukotriene-mediated vasoconstriction.
Although FPL 5723 1 prevented and reversed hypoxic pulmonary vasoconstriction in this study, it had little effect on other hemodynamic variables during hypoxia. Cardiac output is either increased, decreased, or unchanged during hypoxia (18) . The hypoxia-induced increase in both cardiac output and heart rate observed in this study were maintained during the infusion of FPL 5723 1. These results would suggest that the mechanism of the hypoxia-induced increase in pulmonary arterial pressure is different from that which induces the change in cardiac output. The former mechanism is possibly mediated through leukotrienes, the latter possibly through autonomic pathways.
Various doses of FPL 5723 1 were infused prior to the onset of hypoxia to determine the lowest dose that would prevent hypoxic pulmonary vasoconstriction: 1-2 mg . kg-'. min-' of FPL 5723 1 completely inhibited the hypoxia-induced increase in pulmonary arterial pressure and pulmonary vascular resistance; 0.5 mg.
kg-' -min-' was less effective in preventing hypoxic pulmonary vasoconstriction. The effect of exogenous LTD4 in adult sheep can be inhibited by 0.66 mg. kg-' .min-' of FPL 57231 (32) . Therefore, we used a 1 mg. kg-'. min-' infusion during the preinfusion study. To reverse pulmonary hypertension induced by hypoxia, 2 mg . kg-'. min-' was used because higher doses of FPL 5723 1 may be necessary to block existing pulmonary vasoconstriction. This dose of FPL 57231 reverses hypoxic pulmonary vasoconstriction in adult sheep (7).
In the clinical syndrome of PPHN, pulmonary vascular resistance does not fall normally with the initiation of respiration. Pulmonary hypertension is seen in a variety of clinical situations, including meconium aspiration, sepsis, and hyaline membrane disease (34, 35) . There may be a common pathway mediating syndromes that produce pulmonary hypertension. Leukotrienes have been isolated in lung lavage fluids from infants with PPHN, but not in others with pulmonary disease without pulmonary hypertension (14) , suggesting a role for leukotrienes in the pathogenesis of PPHN. Despite the use of supplemental oxygen, mechanical hyperventilation, and nonspecific vasodilators in treating infants with PPHN, the mortality rate remains unacceptably high (35) . Leukotriene inhibition with FPL 5723 1 may be useful in the management of infants with PPHN and other patients with pulmonary hypertension. The results of this and other studies suggest a significant role for leukotrienes in the perinatal control of pulmonary blood flow and pulmonary vascular resistance and in the mediation of hypoxic pulmonary vasoconstriction.
quantitate I3CO2 elimination of breath, demethylation of aminopyrine was found to be positively correlated to age. By 20 wk of age, some infants had rates of elimination similar to those measured in adults. Absorption was excluded as a limiting variable, because no improvement in oxidation rates was found when the aminopyrine was readministered as an intravenous bolus. Changes in nutritional status and route of feeding (enteral versus parenteral) did not prevent the effect of maturation on aminopyrine elimination. Conclusions: 1) maturational differences are seen in the metabolism of aminopyrine; 2) these differences may reflect immaturity of N-demethylase activity or diversion of the liberated formaldehyde into biosynthetic rather than oxidative pathways. (Pediatr Res 19: 441-445, 1985) 
